rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BHVN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Could Graves Data Alter The Investment Case For Biohaven (BHVN)?
      Nov 14Yahoo FinanceBHVN
      Is Biohaven (BHVN) Undervalued After Its Narrower Loss And BHV 1420 Data?
      Oct 30Yahoo FinanceBHVN
      Deutsche Bank Adjusts Biohaven Price Target to $23 From $26, Maintains Buy Rating
      Oct 30Yahoo FinanceBHVN
      Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
      Oct 29Yahoo FinanceBHVN
      Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade
      Oct 29Yahoo FinanceBHVN
      Biohaven presents preclinical data on kidney disease drug candidate
      Oct 26Investing.comBHVN
      Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

      Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel TRAP extracellular protein degrader designed to selectively eliminate the anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies that drive membranous nephropathy (MN).

      Oct 26Yahoo FinanceBHVN
      Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says
      Oct 23Yahoo FinanceBHVN
      Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance
      Oct 23Yahoo FinanceBHVN
      Deutsche Bank Adjusts Biohaven Price Target to $26 From $20, Maintains Buy Rating
      Oct 23Yahoo FinanceBHVN
      RBC Raises Price Target on Biohaven to $22 From $19, Keeps Sector Perform, Speculative Risk
      Oct 23Yahoo FinanceBHVN
      Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade
      Oct 23Yahoo FinanceBHVN
      Biohaven Shares Rise After FDA Accepts Vyglxia Resubmission for Review
      Oct 22Yahoo FinanceBHVN
      Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission - This Plot Is Too Thick For Me
      Oct 22Seeking AlphaBHVN
      Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
      Oct 22Barron'sBHVN
      Biohaven’s previously rejected rare disease drug to get fresh FDA review
      Oct 22Yahoo FinanceBHVN
      Biohaven: Third Time’s The Charm For Troriluzole? (NYSE:BHVN)
      Oct 22Seeking AlphaBHVN
      Why Biohaven's 30% Surge Might Just Be The Beginning

      Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug.

      Oct 22Investor's Business DailyBHVN
      Why Is Biohaven Stock Soaring Today? - Biohaven (NYSE:BHVN)
      Oct 22BenzingaBHVN
      Baird raises Biohaven Pharma stock price target on NDA acceptance
      Oct 22Investing.comBHVN
      BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia
      Oct 22Yahoo FinanceBHVN
      12 Health Care Stocks Moving In Thursday's Pre-Market Session
      Oct 22BenzingaBHVN
      Why is Biohaven stock surging today?
      Oct 22Investing.comBHVN
      Biohaven stock surges 25% on FDA acceptance of drug filing
      Oct 22Investing.comBHVN
      Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
      Oct 10Yahoo FinanceALECGEHCVTRSBHVN
      Biohaven Pharma stock maintained at buy by Canaccord on licensing deal
      Oct 9Investing.comBHVN
      Biohaven partners with Ono in $100m IgG degrader deal

      The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan.

      Oct 9Yahoo FinanceBHVN
      Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement - Biohaven (NYSE:BHVN)

      Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.

      Oct 8BenzingaBHVN
      Raymond James reiterates Strong Buy on Biohaven stock after Japan deal
      Oct 8Investing.comBHVNRJF
      Biohaven licenses IgG degrader portfolio to Japan’s Ono (BHVN:NYSE)

      Biohaven (BHVN) signs a deal with Ono Pharma (OPHLF) to outlicense its MoDE pan IgG degrader portfolio in several Asian countries. Read more here.

      Oct 8Seeking AlphaBHVN
      Biohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in Asia
      Oct 8Yahoo FinanceBHVN
      Biohaven licenses IgG degrader portfolio to Ono for Asia
      Oct 8Investing.comBHVN
      Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
      Oct 8Yahoo FinanceREGNBHVN
      Roche’s AI lab; Biohaven’s pivotal pause

      Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven

      Oct 2Yahoo FinanceBHVN
      Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN)

      Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailBHVN
      Biohaven’s cancer drug data selected for presentation at symposium
      Sep 28Investing.comBHVN
      Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
      Sep 28Yahoo FinanceBHVN
      Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?

      Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is how that market value lines up against the company’s book value relative to the broader pharmaceuticals and biotech industry. Over the past 3 years, Biohaven shareholders have seen the stock decline about 49.3%, which puts the focus squarely on whether its...

      Sep 25Yahoo FinanceBHVN
      Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says

      Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program a

      Sep 18Yahoo FinanceBHVN
      Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
      Sep 11MorningstarBHVN
      Biohaven’s epilepsy drug hit with FDA clinical hold

      Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.

      Sep 11Yahoo FinanceBHVN
      Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN)
      Sep 10Seeking AlphaBHVN
      Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
      Sep 10Barron'sBHVN
      Baird reiterates Biohaven stock rating after regulatory update
      Sep 10Investing.comBHVN
      Biohaven's Ratty Setback; How Xenon Benefits

      Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.

      Sep 10Investor's Business DailyBHVN
      US FDA pauses new enrollment in Biohaven's epilepsy drug trials
      Sep 10ReutersBHVN
      Why Is Biohaven Stock Tumbling Today? - Biohaven (NYSE:BHVN)
      Sep 10BenzingaBHVN
      Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
      Sep 10Yahoo FinanceBHVN
      BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?
      Sep 10Yahoo FinanceBHVN
      Why is Biohaven Pharmaceutical stock sliding today?
      Sep 10Investing.comBHVN

      This is the newest page. Registered accounts read further back.